LEANDRO LARA DO PRADO
Projetos de Pesquisa
Unidades Organizacionais
Instituto Central, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
LIM/17 - Laboratório de Investigação em Reumatologia, Hospital das Clínicas, Faculdade de Medicina
9 resultados
Resultados de Busca
Agora exibindo 1 - 9 de 9
conferenceObject Behcet's Disease Activity: An Important Factor For Immunogenicity Of Unadjuvanted Influenza A/H1N1 Vaccine(2013) PRADO, Leandro L.; SAAD, Carla G. S.; MORAES, Julio C. B.; RIBEIRO, Ana Cristina Medeiros; AIKAWA, Nadia E.; SILVA, Clovis A.; SCHAINBERG, Claudia G.; SAMPAIO-BARROS, Percival D.; PRECIOSO, Alexander R.; ISHIDA, Maria A.; BONFA, Eloisa; GONCALVES, Celio- Ankylosing spondylitis and psoriatic arthritis: revisiting screening of latent tuberculosis infection and its follow-up during anti-tumor necrosis factor therapy in an endemic area(2020) SHIMABUCO, Andrea Yukie; MEDEIROS-RIBEIRO, Ana Cristina de; MIOSSI, Renata; BONFIGLIOLI, Karina Rossi; MORAES, Julio Cesar Bertacini de; GONCALVES, Celio Roberto; SAMPAIO-BARROS, Percival Degrava; GOLDENSTEIN-SCHAINBERG, Claudia; SOUZA, Fernando Henrique Carlos de; PRADO, Leandro Lara do; UGOLINI-LOPES, Michele Remiao; YUKI, Emily Figueiredo Vieira Neves; BONFA, Eloisa; SAAD, Carla Goncalves SchahinOBJECTIVES: To retrospectively evaluate the performance and distinctive pattern of latent tuberculosis (TB) infection (LTBI) screening and treatment in patients with ankylosing spondylitis (AS) and psoriatic arthritis (PsA) under anti-tumor necrosis factor (TNF) therapy and determine the relevance of re-exposure and other risk factors for TB development. METHODS: A total of 135 and 83 patients with AS and PsA, respectively, were evaluated for LTBI treatment before receiving anti-TNF drugs via the tuberculin skin test (TST), chest radiography, and TB exposure history assessment. All subjects were evaluated for TB infection at 3-month intervals. RESULTS: The patients with AS were more often treated for LTBI than were those with PsA (42% versus 30%, p=0.043). The former also presented a higher frequency of TST positivity (93% versus 64%, p=0.002), although they had a lower frequency of exposure history (18% versus 52%, p=0.027) and previous TB (0.7% versus 6%, p=0.03). During follow-up [median, 5.8 years; interquartile range (1QR), 2.2-9.0 years], 11/218 (5%) patients developed active TB (AS, n=7; PsA, n=4). TB re-exposure was the main cause in seven patients (64%) after 12 months of therapy (median, 21.9 months; IQR, 14.2-42.8 months) and five LTBI-negative patients. TB was identified within the first year in four patients (36.3%) (median, 5.3 months; IQR, 1.2-8.8 months), two of whom were LTBI-positive. There was no difference in the TB-free survival according to the anti-TNF drug type/class; neither synthetic drug nor prednisone use was related to TB occurrence (p > 0.05). CONCLUSION: Known re-exposure is the most critical factor for incident TB cases in spondyloarthritis. There are also some distinct features in AS and PsA LTBI screening, considering the higher frequency of LTBI and TST positivities in patients with AS. Annual risk reassessment taking into consideration these peculiar features and including the TST should be recommended for patients in endemic countries.
conferenceObject Distinctive Pattern of LTBI Screening Parameters in Ankylosing Spondylitis (AS) and Psoriatic Arthritis (PsA) in Endemic Areas(2019) SHIMABUCO, Andrea; RIBEIRO, Ana Cristina de Medeiros; MIOSSI, Renata; BONFIGLIOLI, Karina; MORAES, Julio Cesar Bertacini; GONCALVES, Celio; SAMPAIO-BARROS, Percival; GOLDENSTEIN-SCHAINBERG, Claudia; SOUZA, Fernando Henrique; PRADO, Leandro; UGOLINI-LOPES, Michelle Remiao; YUKI, Emily; BONFA, Eloisa; SAAD, Carla Goncalves SchahinconferenceObject DISPENSATION OF IMMUNOBIOLOGICALS IN MODEL OF ASSISTED THERAPY IN THE SUS REDUCES COSTS WITH IMMUNOBIOLOGICAL IN ANKYLOSING SPONDYLITIS(2018) SCOMPARIN-SILVERIO, L. R.; SAAD, C. G. S.; SOUZA, F. H. C.; MIOSSI, R.; RIBEIRO, A. C. M.; WAISBERG, M. G.; BONFIGLIOLI, K. R.; PRADO, L. L.; TEICH, V; BONFA, E.; MORAES, J. C. B.- LTBI SCREENING IN SPONDYLOARTHRITIS PATIENTSPRIOR TO ANTI-TNF TREATMENT AND FOLLOW-UP IN AN ENDEMIC AREA(2019) SHIMABUCO, Andrea; MEDEIROS, Ana; MIOSSI, Renata; BONFIGLIOLI, Karina; MORAES, Julio; GONCALVES, Celio; SAMPAIO-BARROS, Percival D.; GOLDENSTEIN-SCHAINBERG, Claudia; SOUZA, Fernando; PRADO, Leandro; LOPES, Michelle; BONFA, Eloisa; SAAD, Carla
article 6 Citação(ões) na Scopus Anti-alpha-enolase antibodies in Behcet's disease: a marker of mucocutaneous and articular disease activity?(2018) PRADO, L. L.; GONCALVES, C. R.; VIANA, V. T.; SAAD, C. G. S.; BONFA, E.Objective. To assess IgM anti-alphaenolase antibodies (AAEA) in systemic Behget's disease (BD) and its possible association with clinical manifestations and disease activity. Methods. Ninety-seven consecutively selected BD patients were compared to 36 enteropathic spondyloarthritis (ESpA) [24 Crohn's disease (CD) and 12 ulcerative colitis (UC)] patients and 87 healthy controls. 1gM AAEA was detected by immunoblotting. Disease activity was assessed by standardised indexes, Brazilian BD Current Activity Form (BR-BDCAF) for BD and HarveyBradshaw Index (HBI) for CD and UC patients. A second evaluation was performed in BD patients (n=56), regarding IgM AAEA presence, disease activity scores and C-reactive protein (CRP). Results. Higher IgM AAEA prevalence was found in 97 BD (17.7%) compared to ESpA (2.8%) and healthy controls (2.3%), p< O. O01. IgM AAEA frequency was higher in active BD compared to inactive BD (30.2% vs. 7.4%, p=O. O06), a finding confirmed in the second cross-sectional evaluation of 56 of these BD patients (45.5% vs. 13.3%, p=O. 02). Mean BR-BDCAF scores were higher in IgM AAEA positive group on both evaluations (9.1 + 5.4 vs. 4.9 + 4.9, p=O. O02; 5.0 + 4.9 vs. 2.2 + 2.9, p=O. 01, respectively). BD patients with mucocutaneous and articular symptoms presented higher IgM AAEA positivity in the first and second evaluations (64.7% vs. 27.5%, p=O. O05; 36.4% vs. 7.1%, p=0.039 respectively). Conclusions. Our data support the notion that alpha-enolase is a target antigen in BD, particularly associated with disease activity, mucocutaneous and articular involvement. In addition, IgM AAEA may distinguish BD from ESpA, especially in patients with high disease activity.conferenceObject BEHCET'S DISEASE ACTIVITY: AN IMPORTANT FACTOR FOR IMMUNOGENECITY OF UNADJUVANTED INFLUENZA A/H1N1 VACCINE(2013) PRADO, L. L.; SAAD, C. G. S.; MORAES, J. C. B.; RIBEIRO, A. C. M.; AIKAWA, N. E.; SILVA, C. A.; SCHAINBERG, C. G.; SAMPAIO-BARROS, P. D.; PRECIOSO, A. R.; ISHIDA, M. A.; BONFA, E.; GONCALVES, C. R.conferenceObject Anti-Alpha-Enolase Antibodies in Behcet's Disease: A Marker of Articular Disease Activity?(2015) PRADO, Leandro L.; GONCALVES, Celio R.; VIANA, Vilma S. T.; BONFA, Eloisa; SAAD, Carla G. S.conferenceObject Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort(2016) RIBEIRO, Ana C. M.; BONFIGLIOLI, Karin.; MIOSSI, Renata; SAAD, Carla G. S.; MORAES, Julio C. B.; WAISBERG, Mariana G.; SOUZA, Fernando Henrique Carlos de; AIKAWA, Nadia E.; PRADO, Leandro L. do; LOPES, Michelle; SEGURO, Luciana; BONFA, Eloisa